Mainz Biomed sells next-gen CRC screening IP for $1.25M, updates Nasdaq equity compliance

Quantum Cyber N.V.

Entered asset purchase agreement to sell Next Gen IP for $1.25M; closing by April 23, 2026.
Proceeds to be used for settlement of outstanding liabilities and general corporate purposes.
Continues development of pancreatic cancer detection product and explores post-quantum cybersecurity.
Believes stockholders' equity exceeds $2.5M after receiving $6M total from preferred share sale (Feb & March 2026).
Previously wound down ColoAlert product and next-gen colorectal cancer screening development in Feb 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Quantum Cyber N.V. entered into Agreement with third-party purchaser incorporated in Italy valued at $1.25 million (effective 2026-04-09).

Action: entry
Agreement: asset purchase
Counterparty: third-party purchaser incorporated in Italy
Value: $1.25 million
Effective: 2026-04-09

Exact text from the filing

On April 9, 2026, we entered into an asset purchase agreement (the “Agreement”) for the sale of the Next Gen IP to a third-party purchaser incorporated in Italy. Pursuant to the Agreement, we will sell the Next Gen IP to the buyer for a payment of $1.25 million.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Quantum Cyber N.V. filing history →

Source: SEC EDGAR

accession 0001213900-26-044125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.